Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 236 participants.
Also called NCT01410383
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 236 participants
- Sponsor
- Karo Bio AB
- Registry
-
NCT01410383
-
- Other papers using this trial's data
- Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01410383. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
- Acronym
- AKKA
- Condition
- Heterozygous Familial Hypercholesterolaemia
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Eprotirome
- Intervention (Drug)
- Eprotirome
- Lead sponsor
- Karo Bio AB
Record details
- Record id
cardio:ct-nct01410383- Content hash
242bf41379465422a12d621fb6579350f1388d5cebde618d351d9484906769e3